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Abstract
Background. Individuals with autism spectrum disorder (ASD) appear to be at increased risk
of non-affective psychotic disorder (NAPD) and bipolar disorder (BD). However, most
previous studies examined the co-occurrence of ASD and NAPD or BD, ignoring possible
diagnostic bias and selection bias. We used longitudinal data from Dutch psychiatric case
registers to assess the risk of NAPD or BD among individuals with ASD, and compared
the results to those obtained for the Dutch population in earlier studies.
Methods. Individuals with ASD (n = 17 234) were followed up between 16 and 35 years of age.
Kaplan–Meier estimates were used to calculate the risk of NAPD or BD. We conducted
separate analyses to reduce possible bias, including an analysis among individuals diagnosed
with ASD before age 16 years (n = 8337).
Results. Of the individuals with ASD, 23.50% (95% confidence interval 21.87–25.22) were
diagnosed with NAPD and 3.79% (3.06–4.69) with BD before age 35 years. The corresponding
figures for the general population were 0.91% (0.63–1.28) and 0.13% (0.08–0.20). Risk
estimates were substantially lower, but still higher than general population estimates, when
we restricted our analyses to individuals diagnosed with ASD before age 16, with 1.87%
(1.33–2.61) being diagnosed with NAPD and 0.57% (0.21–1.53) with BD before age 25
years. The corresponding figures for the general population were 0.63% (0.44–0.86) and
0.08% (0.05–0.12).
Conclusions. Individuals with ASD are at increased risk of NAPD or BD. This is likely not the
result of diagnostic or selection bias.
Introduction
Recent years have seen a growing interest in the long-term prognosis of individuals with
autism spectrum disorder (ASD), and in particular their risk of developing non-affective
psychotic disorder (NAPD) or bipolar disorder (BD). However, risk estimates vary greatly.
Two reviews reported a range of prevalence figures of NAPD in individuals with ASD from
0% to over 34% (Skokauskas and Gallagher, 2010; Chisholm et al., 2015). Another review
reported a prevalence of BD in individuals with ASD of up to 9% (Vannucchi et al., 2014),
but the authors also noted a general lack of investigations.
Most of these studies examined the co-occurrence of ASD and NAPD or BD, but this can
result in diagnostic and/or selection bias. Since some signs typical of ASD, such as social with-
drawal, are also common in NAPD and BD, some clinicians might erroneously diagnose ASD
based on the assumption that these difficulties were present since early childhood. Selection
bias may occur if individuals with previously unrecognized ASD are diagnosed with ASD
after they have been diagnosed with NAPD or BD.
These sources of bias are less likely in studies in which young individuals with ASD are
followed over time, because NAPD and BD generally do not develop until late adolescence
or adulthood. However, earlier studies with such a design had small sample sizes, with few
including more than 100 (and no more than 200) individuals with some form of autism
(Volkmar and Cohen, 1991; Billstedt et al., 2005; Cederlund et al., 2008; Hutton et al.,
2008, Mouridsen et al., 2008). A Swedish population-based study included individuals regis-
tered with ASD before 16 years of age over an 11-year period (n = 9062) and calculated
their odds of developing NAPD or BD within that period (Selten et al., 2015). Compared
with non-ASD peers, individuals with ASD had a higher risk of developing NAPD or BD
(adjusted odds ratio 4.6 and 4.3, respectively); however, the study did not take into account
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the sequence of diagnoses in time. Overall, more large longitu-
dinal studies examining the risk of NAPD and BD are needed,
especially studies that consider the sequence of diagnoses in
time (ASD preferably before NAPD or BD) and the age at
which ASD is diagnosed.
The current study investigated the risk that individuals with
ASD aged 16–35 years would develop NAPD or BD, using longi-
tudinal data from Dutch psychiatric case registers (PCRs). Several
analyses were conducted to minimize the possible contribution of
diagnostic and selection bias. We compared the risk estimates
with those for the Dutch population reported in earlier studies.
Additionally, we assessed potential risk factors for NAPD or
BD in individuals with ASD.
Methods
Psychiatric case registers
Data were retrieved from two PCRs in the Netherlands (PCR
Northern-Netherlands and PCR Middle-Netherlands), which
received anonymized diagnostic and demographic information
on all patients attending inpatient/outpatient facilities for mental
healthcare in a specified geographical area. We extracted data
collected between 2000 and 2012 by PCR Northern-Netherlands
and between 1999 and 2015 by PCR Middle-Netherlands. Data
for each patient included information on Diagnostic and
Statistical Manual of Mental Disorders (DSM)-IV diagnoses
(diagnosis and date of diagnosis), sex, date of birth, country of
birth, and country of birth of each parent. Informed consent
was not obtained from individual patients, as Dutch privacy law
permits the use of anonymous data for medical research.
Cases
The initial extraction included all individuals registered with a
DSM-IV diagnosis of ASD (codes 299.xx) during the above-
mentioned periods (n = 39 434). Individuals with ASD were
excluded if information on their date of birth, date of first PCR
registration, date of ASD diagnosis, or date of NAPD or BD diag-
nosis (if made) was missing (n = 195), or if the date of the ASD,
NAPD, or BD diagnosis had been registered retroactively (n =
4855), that is, if the diagnosis had been made before 2000 (PCR
Northern-Netherlands), before 1999 (PCR Middle-Netherlands),
or before the first PCR registration. Furthermore, as we were
interested in the risk of NAPD and BD in individuals aged 16–
35 years, we excluded individuals diagnosed with NAPD or BD
at or before 16 years of age (n = 129), who were younger than
16 years when the PCR closed (n = 12 785), or who had been diag-
nosed with ASD when aged 36 or older (n = 4236). In total, 17
234 individuals with ASD were included in the analyses.
Outcomes
The outcome of interest was a diagnosis of NAPD or BD made
between 16 and 35 years of age. NAPD was defined as a
DSM-IV diagnosis of schizophrenia, schizophreniform disorder,
or schizoaffective disorder (codes 295.x), delusional disorder
(code 297.1), or psychotic disorder not otherwise specified (NOS)
or brief psychotic disorder (codes 298.x). BD was defined as a
DSM-IV diagnosis of bipolar I disorder (codes 296.0x, 296.4x,
296.5x, 296.6x, or 296.7), bipolar II disorder (code 296.89), or
BD NOS (296.80). If individuals were diagnosed with both
NAPD and BD (n = 42), we assumed that the last diagnosis
reflected a valid revision of the previous one. In these cases,
only the last diagnosis was used in the analyses but the date of
the previous diagnosis was used as an estimate of the age at
onset. Two individuals were simultaneously diagnosed with
NAPD and BD and were only included in the NAPD analyses.
General population estimates of the cumulative incidence of
NAPD were obtained from a 2-year first-contact study conducted
in The Hague, the Netherlands, in the period 1997–1999 (Selten
et al., 2001). General population estimates of the cumulative inci-
dence of BD were obtained from a population-based cohort study
conducted in the Netherlands in the period 1996–2007 (Kroon
et al., 2013). Incidence rates for different age groups (for
NAPD 15–19, 20–24, 25–29, 30–34 years; for BD 15–24, 25–34
years) by sex were provided by the researchers involved in these
studies and were used to estimate the cumulative incidence.
Statistical analyses
Risk of NAPD or BD
The risk of NAPD among individuals with ASD was calculated
using Kaplan–Meier survival estimates, which reflect the proportion
of individuals with ASDwho had not been diagnosed withNAPD at
a certain age. Individuals were followed up until they were 36 years
old, until NAPD or BD was diagnosed, or until the PCR closed,
whichever came first. Kaplan–Meier estimates for men and
women separately, and their comparison with general population
estimates, are reported in online Supplementary Table S1.
In the first analysis, we estimated the risk of a first diagnosis of
NAPD between ages 16 and 36 among all individuals diagnosed
with ASD before 36 years of age. Here we did not consider the
sequence in which diagnoses were made or the age at which
ASD was diagnosed. Consequently, we expected a greater likeli-
hood of diagnostic bias (i.e. signs of NAPD being mistakenly
diagnosed as ASD) and selection bias (i.e. individuals being recog-
nized and/or registered with ASD due to the development of
NAPD). The follow-up started at the age of first contact with
mental healthcare services for any DSM-IV diagnosis or at age
16, whichever came later.
In the second analysis, we excluded individuals who were diag-
nosed with ASD after they had been diagnosed with NAPD, or
who were diagnosed with ASD and NAPD simultaneously. By
restricting the analysis to individuals still at risk of being diag-
nosed with NAPD at the time they were diagnosed with ASD,
we expected that the influence of diagnostic and selection bias
would be reduced. Follow-up started at age 16 or at the age of
ASD diagnosis, whichever came later.
In the third analysis, we further restricted the analysis to indi-
viduals diagnosed with ASD before 16 years of age. We expected
selection or diagnostic bias to play a minor role if ASD was diag-
nosed at an early age. Of note, individuals diagnosed with NAPD
or BD before 16 years of age had already been excluded.
In the fourth analysis, we restricted the analysis to individuals
diagnosed with ASD after (or at) 16 years of age. In these cases, a
diagnosis of NAPD shortly after ASD was diagnosed may indicate
that ASD was only diagnosed because of the development of
NAPD. Therefore, we also conducted a fifth analysis from
which we excluded individuals diagnosed with NAPD within 1
year of the ASD diagnosis.
The risk of BD among individuals with ASD was calculated
using the same analyses described for NAPD, but with a diagnosis
of BD as the outcome of interest.
2544 R. Schalbroeck et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291718003483
Downloaded from https://www.cambridge.org/core. University of Groningen, on 26 Feb 2020 at 12:35:51, subject to the Cambridge Core terms of use, available at
For general population risk estimates, we calculated the
cumulative incidence of NAPD or BD by subtracting the survivor
function S(t) = {exp[−H(t)]} from 1, in which S denotes the prob-
ability that a member of the general population did not receive a
diagnosis of NAPD or BD up to t years, and H represents the
cumulative hazard function (Cleves et al., 2010). This formula
was equated to S(t) = exp{−∑(incidence(t)·Δt)}, in which we
implemented the NAPD and BD incidence rates for different
age groups, as provided by Selten et al. (2001) and Kroon et al.
(2013). The 95% confidence interval (CI) of the cumulative inci-
dence for the general population was compared with the 95% CIs
of the cumulative incidence for individuals with ASD (1 minus
Kaplan–Meier estimate) to examine whether they significantly
differed. For the general population estimates, CIs were calculated
assuming a Poisson distribution of the number of NAPD/BD
cases (Rothman, 2015). For the comparison of the cumulative
incidence, relative risks (RRs) are also provided.
Risk factors for NAPD or BD
Cox regression analyses were used to identify potential risk factors
for the development of NAPD or BD. For these analyses, we used
information from individuals diagnosed with ASD before age
16 years and from those diagnosed with ASD after (or at) this
age, provided that NAPD or BD was diagnosed at least 1 year
after ASD was diagnosed. We expected that the contribution of
diagnostic or selection bias to the risk estimates would be small
in these individuals.
The following potential risk factors were evaluated: sex, intel-
lectual disability (ID; DSM-IV codes 317, 318.x, 319) present
before or at the moment of the ASD diagnosis, migrant status
based on parental country of birth (non-migrant if both parents
were Dutch, migrant if at least one of the parents had been
born abroad, or other if this information was unknown), ASD
subtype [autistic disorder v. pervasive developmental disorder-not
otherwise specified (PDD-NOS) or Asperger’s syndrome], and
age at ASD diagnosis (four age groups: 0–7, 8–15, 16–25, 26–35
years). Owing to the limited data available for the Cox regression
analyses for BD, migrant status was not included, and the age at
ASD diagnosis was split into three groups (0–15, 16–25, 26–35
years). An alpha of 0.05 was used to examine whether a variable
violated the proportional hazard assumption and to evaluate
whether a variable was significantly related to an increased or
decreased risk of NAPD or BD.
Missing data
Information about sex was missing for six individuals with ASD
(0.03%). Data for these individuals were omitted from Kaplan–
Meier estimates by sex and from the Cox regression analyses.
Table 1. Characteristics of individuals with ASD registered in Dutch PCRs
Characteristic 1. Whole ASD samplea
ASD diagnosed firstb
2. Total 3. ASD < 16c 4. ASD⩾ 16d
5. ASD ⩾ 16, NAPD/BD
not in first yeare
No. ASD cases 17 234 16 715 8337 8378 8197
Male sexf 76.07% 75.98% 78.77% 73.20% 72.99%
Autistic disorder 10.49% 10.25% 7.51% 12.97% 12.79%
Migrant 4.07% 3.95% 4.31% 3.60% 3.49%
IDg 10.51% 10.45% 8.36% 12.53% 12.49%
Age start follow-up, mean (S.D.) 18.55 (4.51) 19.17 (5.02) 16.00 (0.00) 22.32 (5.52) 22.30 (5.52)
Age end follow-up, mean (S.D.) 23.15 (5.60) 23.09 (5.61) 19.45 (2.38) 26.72 (5.55) 26.79 (5.53)
Total observation time in years 79 333 65 641 28 784 36 857 36 824
No. cases with NAPD 845 381 68 313 154
Male sexf 80.81% 81.32% 74.63% 82.75% 82.47%
Autistic disorder 17.75% 16.54% 8.8% 18.21% 12.34%
Migrant 7.69% 7.87% 11.76% 7.03% 5.19%
IDg 13.02% 13.12% 13.24% 13.10% 11.69%
No. cases with BD 116 61 13 48 26
Male sexf 65.52% 62.30% 46.15% 66.67% 53.85%
Autistic disorder 12.93% 11.48% 7.69% 12.5% 19.23%
Migrant 6.03% 3.28% 0.00% 4.17% 0.00%
IDg 11.21% 13.11% 15.38% 12.5% 11.54%
ASD, autism spectrum disorder; NAPD, non-affective psychotic disorder; BD, bipolar disorder; ID, intellectual disability; S.D., standard deviation.
a No restrictions with regard to age or sequence in time of diagnosis (ASD before or after NAPD/BD).
b Restricted to ASD cases still at risk of a first diagnosis of NAPD or BD at the time of the ASD diagnosis.
c Restricted to cases diagnosed with ASD before age 16.
d Restricted to cases diagnosed with ASD after (or at) age 16.
e Restricted to cases diagnosed with ASD after (or at) age 16, in which an NAPD or BD diagnosis was not made within the first year after the ASD diagnosis.
f Calculated over total number of cases. Information about sex was missing for n = 6.
g Diagnosed before or simultaneously with ASD.
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Migrant status could not be ascertained in 3019 individuals
(17.5%). As described above, in the Cox regression analyses the
migrant status of these individuals was coded as ‘other’.
Software
Data were prepared with SPSS version 22.0 (IBM). STATA version
13.1 (StataCorp) was used to calculate Kaplan–Meier survival esti-
mates (using the sts list and sts graph commands) and for Cox
regression analyses and corresponding proportional hazards
tests (using the stcox and estat phtest commands).
Results
Risk of NAPD or BD
Table 1 gives an overview of the characteristics of the individuals
with ASD included in each analysis. Figure 1 shows the estimated
risk of NAPD or BD in each analysis, which are compared with
general population estimates in Table 2.
The results of the first analysis, which did not take into
account the age at ASD diagnosis or sequence of diagnoses,
showed that an estimated 24.36% (95% CI 22.68–26.14) of indivi-
duals with ASD were diagnosed with NAPD and an estimated
4.00% (95% CI 3.23–4.95) were diagnosed with BD before
36 years of age.
For the second analysis, we excluded 464 of 845 individuals
with NAPD (54.91%) and 55 of 116 individuals with BD
(47.41%), as these diagnoses had been made before or simultan-
eously with an ASD diagnosis. Of the remaining individuals
with ASD, 13.27% (95% CI 11.80–14.91) were diagnosed with
NAPD and 2.39% (95% CI 1.77–3.24) were diagnosed with BD
before 36 years of age.
In the third analysis, we restricted to individuals diagnosed
with ASD before 16 years of age. These individuals could not
be followed up until 36 years of age because the PCRs were
not operational long enough, but an estimated 1.87% (95% CI
1.33–2.61) were diagnosed with NAPD and 0.57% (95% CI
0.21–1.53) with BD before 25 years of age.
We restricted the fourth analysis to individuals diagnosed with
ASD at or after 16 years of age. The results showed that an esti-
mated 16.46% (95% CI 14.37–18.82) were diagnosed with
NAPD and an estimated 2.61% (95% CI 1.93–3.52) with BD
before 36 years of age. In total, 159 of 313 of individuals diag-
nosed with NAPD (50.80%) and 22 of 48 individuals diagnosed
with BD (45.83%) had been diagnosed within 1 year of the
ASD diagnosis. After exclusion of these individuals in the fifth
analysis, an estimated 7.90% (95% CI 6.70–9.31) of individuals
were diagnosed with NAPD and an estimated 1.35% (95% CI
0.89–2.04) were diagnosed with BD before 36 years of age.
Overall, 623 of 845 NAPD diagnoses (73.72%) and 77 of 116
BD diagnoses (66.38%) were made before, simultaneously with,
or within 1 year of the ASD diagnosis.
In general, the risks of NAPD and BDwere higher in individuals
with ASD than in the general population (with non-overlapping
95% CIs), irrespective of the restrictions that we applied to the
analysis. These differences were not explained by sex, as both
men and women with ASD had a higher risk of developing
NAPD or BD than did men and women without ASD. As shown
in online Supplementary Table S1, risk estimates for NAPD and
BD among men diagnosed with ASD before 16 years of age were
an exception to this. The risk estimates were larger than the risk
estimates among men in the general population, but the 95% CIs
were partially overlapping.
Risk factors for NAPD or BD
We then examined potential risk factors for NAPD. The propor-
tional hazards assumption was violated for the variable sex (χ2 =
6.94, p = 0.008), but not for other variables (all p values >0.05).
Inspection of the data showed that the risk of NAPD among
men and women with ASD was similar between 16 and 25 years
of age, but diverged between 26 and 35 years of age. For this rea-
son, we added a term for the interaction between time (follow-up
during ages 16–25 v. 26–35) and sex to the analysis.
We initially conducted univariable analyses and subsequently
added all variables to a multivariable model (see Table 3).
Univariable analyses showed that men with ASD had a higher
Fig. 1. The Kaplan–Meier survival estimates per analysis showing the estimated proportion of individuals with ASD registered in Dutch PCRs remaining without a
diagnosis of NAPD (left panel) or BD (right panel) with increasing age. Note that the scale on the y-axis differs for the two figures. The large increase in risk of NAPD
after age 26 years in individuals who were diagnosed with ASD before age 16 is the result of a small number of remaining cases.
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1. Whole ASD samplec
ASD diagnosed firstd
2. Total 3. ASD < 16e 4. ASD ⩾ 16f
5. ASD⩾ 16, NAPD/BD
not in first yearg
% RR % RR % RR % RR % RR
NAPD
15–19h 0.27% (0.18–0.40) 2.38% (2.08–2.73)* 8.81 1.68% (1.41–2.00)* 6.22 0.98% (0.74–1.30)* 3.63 4.51% (2.96–6.82)* 16.70 0.60% (0.36–0.99) 2.22
15–24 0.63% (0.44–0.86) 7.79% (7.12–8.53)* 12.37 4.47% (3.92–5.10)* 7.10 1.87% (1.33–2.61)* 2.97 8.03% (6.32–10.19)* 12.75 2.55% (2.02–3.20)* 4.05
15–29 0.81% (0.57–1.12) 15.80% (14.62–17.07)* 19.51 8.75% (7.73–9.89)* 10.80 11.45% (9.60–13.62)* 14.14 5.40% (4.52–6.45)* 6.67
15–34 0.91% (0.63–1.28) 23.50% (21.87–25.22)* 25.82 12.79% (11.37–14.38)* 14.05 16.20% (14.12–18.55)* 17.80 7.60% (6.44–8.96)* 8.35
15–35 24.36% (22.68–26.14) 13.27% (11.80–14.91) 16.46% (14.37–18.82) 7.90% (6.70–9.31)
BD
15–19h 0.24% (0.15–0.37) 0.20% (0.12–0.33) 0.16% (0.08–0.32) 0.32% (0.14–0.74) 0.12% (0.04–0.39)
15–24 0.08% (0.05–0.12) 1.19% (0.92–1.53)* 14.88 0.83% (0.59–1.16)* 10.38 0.57% (0.21–1.53)* 7.13 1.03% (0.69–1.53)* 12.88 0.51% (0.30–0.86)* 6.38
15–29 2.29% (1.83–2.87) 1.57% (1.15–2.15) 1.79% (1.29–2.47) 0.91% (0.59–1.41)
15–34 0.13% (0.08–0.20) 3.79% (3.06–4.69)* 29.15 2.29% (1.69–3.1)* 17.62 2.50% (1.85–3.39)* 19.23 1.35% (0.89–2.04)* 10.38
15–35 4.00% (3.23–4.95) 2.39% (1.77–3.24) 2.61% (1.93–3.52) 1.35% (0.89–2.04)
CIs, confidence intervals; NAPD, non-affective psychotic disorder; BD, bipolar disorder; ASD, autism spectrum disorder; RR, relative risk.
a, b Retrieved from Selten et al. (2001; NAPD) and Kroon et al. (2013; BD).
c No restrictions with regard to age or sequence in time of diagnosis (ASD before or after NAPD/BD).
d Restricted to ASD cases still at risk of a first diagnosis of NAPD or BD at the time of the ASD diagnosis.
e Restricted to cases diagnosed with ASD before age 16.
f Restricted to cases diagnosed with ASD after (or at) age 16.
g Restricted to cases diagnosed with ASD after (or at) age 16, in which an NAPD or BD diagnosis was not made within the first year after the ASD diagnosis.
h Individuals from the general population were included from age 15 onward. ASD cases were included from age 16 onward.
























s of use, available at
risk of NAPD than women with ASD, but only during the
follow-up between age 26 and age 35 years. This risk remained
increased in the multivariable model. Univariable analyses also
showed an increased risk of NAPD among migrants than
among native Dutch individuals ( p = 0.04). In the multivariable
model, this relative risk was of borderline statistical significance
Table 3. Cox regression analyses examining potential risk factors for NAPD or BD among individuals with ASD registered in Dutch PCRs (n = 16 528)
ASD < 16 or ASD ⩾ 16 without NAPD/BD diagnosis in first yeara
Univariable analyses Multivariable analyses
Variable HR (95% CI) p value HR (95% CI) p value
NON-AFFECTIVE PSYCHOTIC DISORDERb
Sex
Female (follow-up during ages 16–25 years) Reference Reference
Male (follow-up during ages 16–25 years) 1.03 (0.71–1.50) 0.87 1.05 (0.72–1.52) 0.81
Female (follow-up during ages 26–35 years) Reference Reference
Male (follow-up during ages 26–35 years) 2.43 (1.16–5.10) 0.02* 2.46 (1.17–5.16) 0.02*
Migrant status
Dutch Reference Reference
Migrant 1.72 (1.03–2.88) 0.04* 1.64 (0.97–2.78) 0.07
Unknown 0.88 (0.62–1.24) 0.47 0.87 (0.62–1.24) 0.45
ID
No comorbid ID Reference Reference
Comorbid ID 1.17 (0.78–1.76) 0.44 1.20 (0.80–1.81) 0.38
ASD subtype
Asperger’s syndrome/PDD-NOS Reference Reference
Autistic disorder 1.03 (0.68–1.57) 0.89 1.01 (0.66–1.55) 0.96
Age ASD diagnosis
0–7 Reference Reference
8–15 1.71 (0.24–12.43) 0.60 1.64 (0.23–11.92) 0.63
16–25 1.95 (0.26–14.39) 0.51 1.88 (0.25–13.89) 0.54




Male 0.33 (0.18–0.63) 0.001** 0.34 (0.18–0.63) 0.001**
ID
No comorbid ID Reference Reference
Comorbid ID 1.27 (0.50–3.26) 0.62 1.07 (0.41–2.77) 0.90
ASD subtype
Asperger’s syndrome/PDD-NOS Reference Reference
Autistic disorder 1.53 (0.63–3.67) 0.35 1.52 (0.62–3.71) 0.36
Age ASD diagnosis
0–15 Reference Reference
16–25 1.05 (0.44–2.47) 0.92 0.97 (0.41–2.28) 0.94
26–35 1.63 (0.32–8.36) 0.56 1.42 (0.28–7.29) 0.68
NAPD, non-affective psychotic disorder; BD, bipolar disorder; ASD, autism spectrum disorder; HR, hazard ratio; CI, confidence interval; ID, intellectual disability.
a Analyses were restricted to cases diagnosed with ASD before age 16 and cases diagnosed with ASD after (or at) age 16 who remained without NAPD and BD diagnoses for at least 1 year.
b 221 cases diagnosed with NAPD.
c 39 cases diagnosed with BD.
*p < 0.05.
**p < 0.001.
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( p = 0.07). We found no other significant univariable or multi-
variable results (all p values >0.05).
In the analysis of risk factors for BD, none of the variables vio-
lated the proportional hazards assumption (all p values >0.05).
Univariable analyses showed that men with ASD had a lower
risk of BD than did women with ASD. This finding remained
significant in the multivariable analysis. No other variables were
significantly related to risk of BD (all p values >0.05).
Discussion
The results of the current study show that men and women with
ASD are at increased risk of developing NAPD or BD. Men had a
relatively higher risk of developing NAPD and women a relatively
higher risk of developing BD.
It is difficult to estimate the contribution of bias to the
variability in risk reported in earlier studies. However, this
study confirms and extends those earlier findings by showing
that the increased risks persist after adjusting for potential diag-
nostic and selection bias. That is, when we restricted our analyses
to individuals already diagnosed with ASD before age 16, approxi-
mately 1.87% were diagnosed with NAPD and 0.57% with BD by
25 years of age (Table 2, analysis 3). We obtained similar results
when we restricted our analyses to individuals diagnosed with
ASD after 16 years of age who were not diagnosed with NAPD
or BD within a year of the ASD diagnosis (Table 2, analysis 5).
Of these individuals, 2.55% were diagnosed with NAPD and
0.51% with BD by 25 years of age, which increased up to 7.90%
and 1.35% by 36 years of age, respectively.
Strikingly, we found that 74% of NAPD diagnoses and 66% of
BD diagnoses were made before, simultaneously with, or within 1
year of the ASD diagnosis. An earlier study that followed up chil-
dren diagnosed with ASD also reported that a subsequent diagno-
sis of schizophrenia spectrum disorder was most often made
within a year (Maibing et al., 2015). How can these observations
be explained? One possibility is that these individuals had had a
milder form of autism since childhood that was only recognized
by healthcare services when their mental health deteriorated.
Alternatively, some clinicians may have forgotten that autism-like
signs and symptoms are part of NAPD and assume too readily
that these have been present since early childhood. This interpret-
ation fits with the observation of Kendler (2016) that some
clinicians equate ‘schizophrenia’ with its DSM criteria only. It is
less clear whether such confusion exists between ASD and BD,
although signs such as irritability and being overly talkative
appear in both disorders and may result in similar confusion.
The sex difference in the risk of developing NAPD or BD war-
rants further investigation, as previous studies show mixed results
(Stahlberg et al., 2004; Billstedt et al., 2005; Hofvander et al., 2009;
Lugnegard et al., 2011; Croen et al., 2015). The same applies to the
finding that the risk of NAPD was high among migrants with ASD.
We found no relation between risk of NAPD or BD and DSM-IV
subtypes of ASD or age at ASD diagnosis. Furthermore, we did
not replicate the finding of Selten et al. (2015), who reported that
individuals with ASD and ID had a lower risk of developing
NAPD and BD than peers without such disability.
The current study has several strengths. To the best of our
knowledge, it is the largest to study the risk of NAPD or BD in
individuals with ASD. Furthermore, we conducted longitudinal
analyses and took steps to avoid diagnostic and selection bias.
However, the study also has a number of limitations. First, general
population risk estimates were retrieved from previous studies,
which collected data in partially non-overlapping periods and
geographical areas. The study of Selten et al. (2001) was con-
ducted in The Hague, which is a large city in the Netherlands,
whereas our data were partially collected in more rural, northern
parts of the Netherlands. Since the risk of psychosis is reported to
be higher in urban areas (e.g. van Os et al., 2001), the relative risk
of NAPD in individuals with ASD may have been underestimated.
As Kroon et al. (2013) excluded individuals with BD and
co-morbid ID, the relative risk of BD among individuals with
ASD may have been overestimated. A second limitation is that
misdiagnosis cannot entirely be excluded as an explanation for
some findings, as we did not have information about the diagnos-
tic process. In this respect, the availability of extensive diagnostic
information can be seen as a strength of some of the previous
smaller studies (e.g. Stahlberg et al., 2004; Billstedt et al., 2005;
Lugnegard et al., 2011; Joshi et al., 2013).
There is still much uncertainty about why individuals with
ASD have an increased risk of NAPD and BD (Padgett et al.,
2010 Chisholm et al., 2015). Understanding the mechanisms
underlying the increased risk will be an important next step for
the prevention and treatment of these disorders in individuals
with ASD. Shared risk factors, such as genetic overlap between
ASD, NAPD, and BD (Carroll and Owen, 2009; Cross-Disorder
Group of the Psychiatric Genomics Consortium, 2013), may
increase the risk of all three disorders. Individuals with ASD
may also be exposed to environmental risk factors, such as an
urban upbringing (Lauritsen et al., 2014), or psychosocial factors,
such as social exclusion or childhood trauma (Cappadocia et al.,
2012; Kerns et al., 2015), that increase the risk of developing
NAPD and/or BD (Read et al., 2005; Laursen et al., 2007; van
Dam et al., 2012; Selten et al., 2013; Cunningham et al., 2016).
Additionally, it may be worthwhile to consider the possibility
that there are different risk factors for distinct, DSM-independent,
autism subtypes (Chisholm et al., 2015).
In conclusion, the current study showed that individuals with
ASD are at increased risk of developing NAPD or BD. These
results are likely not the result of diagnostic or selection bias.
Future research should examine the mechanisms underlying
these increased risks.
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